Drug Interactions Corner

Back to articles

Pharmacogenetic testing: Opportunities emerging for antidepressants

KEY POINT

Genetic variations (polymorphisms) in the serotonin transporter gene (5-HTT) or the norepinephrine transporter gene (NET) may determine whether a patient will respond to treatment with selective serotonin reuptake inhibitors (SSRIs) or norepinephrine reuptake inhibitors (NRIs), respectively. The findings of a recent study, if confirmed in larger studies, have important implications for determining initial treatments for patients with depression.